Results for tag: "Arformoterol"

Arformoterol is a long-acting beta-2 agonist (LABA) used to treat chronic obstructive pulmonary disease (COPD) and asthma. It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is typically used in combination with an inhaled corticosteroid (ICS) to provide long-term control of COPD and asthma symptoms. Arformoterol is available in both inhalation and oral forms, and is typically taken twice daily. Arformoterol is a relatively new drug, and is not as widely used as other LABAs such as salmeterol and formoterol. However, it has been shown to be more effective than other LABAs in improving lung function and reducing COPD exacerbations. It is also less likely to cause side effects such as tremor and palpitations. The arformoterol market is an important part of the respiratory drugs market, as it provides an effective treatment option for COPD and asthma patients. It is expected to continue to grow in the coming years, as more patients are diagnosed with these conditions and the need for effective treatments increases. Some of the major companies in the arformoterol market include GlaxoSmithKline, Merck, Novartis, and Teva Pharmaceuticals. Show Less Read more